What does kisspeptin do in men?

Kisspeptin signals the brain-pituitary pathway that controls reproductive hormones. Small studies in men found short-term rises in LH and testosterone, and a separate trial found changes in desire-related brain activity and physical arousal. These findings show a biological response, but they do not establish that kisspeptin provides lasting symptom improvement with routine treatment.

Does kisspeptin raise testosterone in men?

It can raise testosterone for a short time in monitored infusion studies. In one six-man crossover experiment, average testosterone rose about 15% during the kisspeptin condition. That result does not show how long the change lasts or whether a man with symptoms will benefit. The response also depends on whether the rest of the hormone pathway can function.

Is there a standard kisspeptin dosage for men?

No. There is no standardized, FDA-approved dose for men. Published studies used different forms of kisspeptin, routes, and research-infusion patterns, so their numbers do not translate directly to a home prescription. A prescriber decides the form, amount, timing, and follow-up from the treatment goal, medical history, medications, baseline hormone results, and response.

Is kisspeptin the same as PT-141?

No. Kisspeptin starts with reproductive-hormone signaling and has also been studied for sexual-brain processing. PT-141, or bremelanotide, acts on melanocortin receptors involved in sexual response. The two compounds ask different biological questions, so a provider's choice depends on whether the concern is desire, erections, hormone signaling, or another cause.

Is kisspeptin approved for men?

No. Kisspeptin is not FDA-approved for men or for any other use, and compounded formulations are not FDA-approved. The human evidence is still based on small, mostly short studies. A licensed provider may nevertheless prescribe a compounded formulation after reviewing the individual case, with the decision and monitoring plan handled between patient and doctor.

Kisspeptin for Men: What the Studies Really Show

Kisspeptin for men is being studied for two related reasons: it can prompt the body's own reproductive-hormone signals, and it may affect how the brain responds to sexual cues. Small human studies have found short-term changes in testosterone, desire-related brain activity, and physical arousal. They haven't yet shown what happens with ordinary use over months, and there is no standard dose for men.

What kisspeptin may mean for men

Kisspeptin is a peptide, a short chain of amino acids that acts as a signal in the body. It starts high in the hormone pathway. In the hypothalamus, the small brain region that coordinates hormones, it prompts release of gonadotropin-releasing hormone (GnRH), the message that tells the pituitary gland to act.

The pituitary, a hormone-control gland below the brain, then releases luteinizing hormone (LH), which tells the testes to make testosterone. It also releases follicle-stimulating hormone (FSH), a signal involved in sperm production. That is why researchers are interested in kisspeptin for low reproductive-hormone signaling. How kisspeptin works in the body covers that pathway in more detail.

This is not the same as supplying testosterone from outside the body. Kisspeptin asks an existing brain-pituitary-testes pathway to respond. Whether it can respond is part of what a clinician has to work out.

What studies of kisspeptin for men actually did

The best-known men's libido study was careful, but it was small and brief. In a 2023 randomized crossover trial, meaning each participant received kisspeptin and placebo on separate visits, 32 men with hypoactive sexual desire disorder completed the study. That diagnosis means persistently low desire that causes personal distress.

The men received one 75-minute intravenous infusion of kisspeptin-54 in a research center. During sexual videos, researchers used functional MRI, a scan that tracks blood-flow changes as a sign of brain activity, and measured physical arousal. Kisspeptin changed activity in parts of the sexual-processing network. Penile tumescence, a measured increase in firmness, was up to 56% greater than with placebo near the end of one video task. The trial also found a small improvement in reported happiness about sex. No side effects or adverse events were reported during those monitored visits (Mills et al., JAMA Network Open 2023).

Those results do not show that an injection produces a lasting libido change. The study tested one infusion, one day, and responses to cues in a laboratory. It did not test a take-home treatment or compare different long-term schedules.

Earlier hormone studies answer a narrower question: can the male hormone pathway respond at all? In a double-blind crossover study of six healthy men, a 90-minute kisspeptin-54 infusion more than doubled average LH compared with saline, from 4.2 to 10.8 units per liter. Average testosterone rose about 15%, from 21.7 to 24.9 nmol/L (Dhillo et al., Journal of Clinical Endocrinology & Metabolism 2005). These were short-term laboratory changes, not evidence of durable symptom improvement.

Fresh 2026 data shows why timing matters

As of September 6, 2026, the day this article was written, the newest relevant study was published August 3, 2026, in the European Journal of Endocrinology. It enrolled 15 healthy men in a randomized, single-blind, placebo-controlled study of kisspeptin-10 delivered by subcutaneous infusion, meaning a continuous flow under the skin.

The LH response became smaller during five days of continuous exposure. A separate pattern with a daily break kept LH and FSH above placebo through 12 days, while the receptor still responded at the end (Yeung et al., European Journal of Endocrinology 2026). This was hormone physiology in healthy volunteers, not a treatment study for low desire or low testosterone. Its practical message is modest: the pattern of exposure matters, so a forum number is not a medical plan.

Kisspeptin and PT-141 take different routes

Kisspeptin and PT-141 can appear in the same sexual-health conversation, but they are not substitutes. Kisspeptin begins with reproductive-hormone signaling and has also been studied for sexual-brain processing. PT-141, also called bremelanotide, activates melanocortin receptors, docking points on nerve cells involved in sexual response. It is not intended to raise LH or testosterone.

The federal Vyleesi label says the branded bremelanotide product is for certain premenopausal women with low sexual desire and is not indicated for men (Vyleesi prescribing information). Research on PT-141 in men asks a different question, centered more on arousal and erections; PT-141 for men explains that evidence and its limits. A provider would choose between these pathways based on the problem being evaluated, not because both compounds are discussed as libido peptides.

Kisspeptin dosage for men is not a fixed number

There is no FDA-approved kisspeptin product or standardized dose for men, and the compounded formulation offered here is not FDA-approved (FDA briefing document, 2024). A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.

Published protocols are not a menu. The libido trial used kisspeptin-54 through an IV for 75 minutes. The 2026 study used kisspeptin-10 through hours-long research infusions. Many current conversations about compounded therapy center on kisspeptin-10, a shorter version of the signal. Those routes, forms, and concentrations cannot be converted into a home syringe amount by copying one number.

A prescriber starts with the actual goal: low desire, suspected low testosterone, or a fertility concern are not the same problem. They also consider morning hormone results, LH and FSH, other medications, pituitary or testicular conditions, and whether a follow-up lab result would change the plan. The prescription determines the form, amount, timing, and monitoring.

That may feel less tidy than a dosing chart. It is also the honest answer the research supports.

What the short safety record can and cannot tell us

One monitored infusion without reported adverse events is reassuring only for that narrow setting. It cannot establish long-term safety. The FDA's compounded-peptide safety page says kisspeptin-10 may carry immune-response and peptide-impurity risks, while safety information for proposed routes remains limited (FDA safety information).

That makes the source and the follow-up important. A compounded medication comes from a licensed pharmacy for an individual prescription. It is different from a grey-market vial with no clinician responsible for deciding whether the compound fits the person or for interpreting a hormone change. Kisspeptin side effects goes deeper on what has and has not been reported.

What a responsible visit looks like

A useful visit separates low desire from erectile difficulty and from low testosterone. Sleep, stress, medications, depression, relationship strain, and underlying hormone problems can point in different directions. Kisspeptin does not erase those differences.

At Promise, a licensed provider reviews every request, and not everyone qualifies. If a prescription makes sense, the provider sets the plan and follow-up; if the evidence or medical history does not support it, the provider can decline or ask for more information.

The questions worth bringing are simple: which form is being prescribed, what result would count as meaningful, which labs will be followed, and what would make the plan stop or change.